WHO WE ARE

MASHNET is a global network of thought leaders dedicated to innovating metabolic dysfunction-associated steatohepatitis (MASH) care delivery, featuring a network of affiliated health systems and industry partners. MASHNET promotes the discovery, development and optimization of care pathways and interventions that align key stakeholders, ensure appropriateness of and linkage to care, and enhance the patient experience.

Since MASHNET was founded in 2016, we have been growing our diverse network of high-performing, population health-focused member organizations. We recognized a need for improved MASH care delivery, including identifying patients earlier in their disease progression. Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than 30 percent of adults in the United States, and it is among the most common causes of liver disease. If not diagnosed or managed, MASLD can cause liver fibrosis and progress to MASH or liver cirrhosis.

Our network is solving key challenges across the MASH care continuum by conducting real-world evidence studies to advance research in patient identification, diagnostic pathways, risk stratification, and novel interventions. We aim to promote international MASH awareness and education, ultimately improving patient outcomes. MASHNET is one of seven Networks of Excellence under Petauri Kinect and headquartered in NYC.